Last reviewed · How we verify
ERAS-007
At a glance
| Generic name | ERAS-007 |
|---|---|
| Sponsor | Erasca, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (PHASE1, PHASE2)
- A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (PHASE1)
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERAS-007 CI brief — competitive landscape report
- ERAS-007 updates RSS · CI watch RSS
- Erasca, Inc. portfolio CI